A review of denosumab for the treatment of osteoporosis
Tsuyoshi Miyazaki,1,2 Fumiaki Tokimura,1 Sakae Tanaka3 1Department of Orthopedic Surgery, 2Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan; 3Department of Orthopedic Surgery, Faculty of Medicine, University of Tokyo, Bun...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-04-01
|
| Series: | Patient Preference and Adherence |
| Online Access: | http://www.dovepress.com/a-review-of-denosumab-for-the-treatment-of-osteoporosis-a16402 |
| _version_ | 1818823620496982016 |
|---|---|
| author | Miyazaki T Tokimura F Tanaka S |
| author_facet | Miyazaki T Tokimura F Tanaka S |
| author_sort | Miyazaki T |
| collection | DOAJ |
| description | Tsuyoshi Miyazaki,1,2 Fumiaki Tokimura,1 Sakae Tanaka3 1Department of Orthopedic Surgery, 2Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan; 3Department of Orthopedic Surgery, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan Abstract: Osteoporosis is an age-related systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. Bone remodeling involves two types of cells: osteoblasts and osteoclasts. Receptor activator of nuclear factor-κB ligand (RANKL) is a key regulator of the formation and function of bone-resorbing osteoclasts, and its cell surface receptor, receptor activator of nuclear factor-κB (RANK), is expressed by both osteoclast precursors and mature osteoclasts. Denosumab is a fully human monoclonal anti-RANKL antibody that inhibits the binding of RANKL to RANK, thereby decreasing osteoclastogenesis and bone-resorbing activity of mature osteoclasts. Although there are many medications available for the treatment of osteoporosis, inhibition of RANKL by denosumab has been shown to significantly affect bone metabolism. Denosumab appears to be a promising, highly effective, and safe parenteral therapy with good adherence for osteoporosis. Moreover, denosumab may be cost-effective therapy compared with existing alternatives. Therefore, in this review, we focus on studies of denosumab and the risks and benefits identified for this type of treatment for osteoporosis. Keywords: bone resorption, OPG, osteoclast, RANKL |
| first_indexed | 2024-12-18T23:42:52Z |
| format | Article |
| id | doaj.art-69704ab0b1684c1f8b67965d9ffecd65 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-18T23:42:52Z |
| publishDate | 2014-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-69704ab0b1684c1f8b67965d9ffecd652022-12-21T20:47:20ZengDove Medical PressPatient Preference and Adherence1177-889X2014-04-012014default46347116402A review of denosumab for the treatment of osteoporosisMiyazaki TTokimura FTanaka STsuyoshi Miyazaki,1,2 Fumiaki Tokimura,1 Sakae Tanaka3 1Department of Orthopedic Surgery, 2Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan; 3Department of Orthopedic Surgery, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan Abstract: Osteoporosis is an age-related systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. Bone remodeling involves two types of cells: osteoblasts and osteoclasts. Receptor activator of nuclear factor-κB ligand (RANKL) is a key regulator of the formation and function of bone-resorbing osteoclasts, and its cell surface receptor, receptor activator of nuclear factor-κB (RANK), is expressed by both osteoclast precursors and mature osteoclasts. Denosumab is a fully human monoclonal anti-RANKL antibody that inhibits the binding of RANKL to RANK, thereby decreasing osteoclastogenesis and bone-resorbing activity of mature osteoclasts. Although there are many medications available for the treatment of osteoporosis, inhibition of RANKL by denosumab has been shown to significantly affect bone metabolism. Denosumab appears to be a promising, highly effective, and safe parenteral therapy with good adherence for osteoporosis. Moreover, denosumab may be cost-effective therapy compared with existing alternatives. Therefore, in this review, we focus on studies of denosumab and the risks and benefits identified for this type of treatment for osteoporosis. Keywords: bone resorption, OPG, osteoclast, RANKLhttp://www.dovepress.com/a-review-of-denosumab-for-the-treatment-of-osteoporosis-a16402 |
| spellingShingle | Miyazaki T Tokimura F Tanaka S A review of denosumab for the treatment of osteoporosis Patient Preference and Adherence |
| title | A review of denosumab for the treatment of osteoporosis |
| title_full | A review of denosumab for the treatment of osteoporosis |
| title_fullStr | A review of denosumab for the treatment of osteoporosis |
| title_full_unstemmed | A review of denosumab for the treatment of osteoporosis |
| title_short | A review of denosumab for the treatment of osteoporosis |
| title_sort | review of denosumab for the treatment of osteoporosis |
| url | http://www.dovepress.com/a-review-of-denosumab-for-the-treatment-of-osteoporosis-a16402 |
| work_keys_str_mv | AT miyazakit areviewofdenosumabforthetreatmentofosteoporosis AT tokimuraf areviewofdenosumabforthetreatmentofosteoporosis AT tanakas areviewofdenosumabforthetreatmentofosteoporosis AT miyazakit reviewofdenosumabforthetreatmentofosteoporosis AT tokimuraf reviewofdenosumabforthetreatmentofosteoporosis AT tanakas reviewofdenosumabforthetreatmentofosteoporosis |